1
|
Abe M, Yamashita H, Jinno S, Custance O, Toki H. Reduction of noise induced by power supply lines using phase-locked loop. Rev Sci Instrum 2022; 93:113704. [PMID: 36461473 DOI: 10.1063/5.0124433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 10/09/2022] [Indexed: 06/17/2023]
Abstract
An experimental implementation for the reduction of power-line noise in delicate signal detection is presented. This implementation improves the signal-to-noise ratio without limiting the bandwidth of the measurement. A sinusoidal wave and its harmonics, both synchronized with the frequency of the power line, are used to cancel out the power supply noise induced in the measurement signal. The wave and the harmonics are generated via a phase-locked loop implementation. Their amplitude and phase are adjusted, and then they are added to the measurement signal using a series of operational amplifiers to compensate for the noise. Although we applied this method to the particular case of scanning tunneling microscopy measurements, considerably improving the image quality, our implementation can be applied to other measurement systems for which noise from the power lines can compromise the signal detection.
Collapse
Affiliation(s)
- M Abe
- Graduate School of Engineering Science, Osaka University, 1-3, Machikaneyama-Cho, Toyonaka, Osaka 560-8531, Japan
| | - H Yamashita
- Graduate School of Engineering Science, Osaka University, 1-3, Machikaneyama-Cho, Toyonaka, Osaka 560-8531, Japan
| | - S Jinno
- Graduate School of Engineering Science, Osaka University, 1-3, Machikaneyama-Cho, Toyonaka, Osaka 560-8531, Japan
| | - O Custance
- National Institute of Materials Science (NIMS), Sengen 1-2-1, Tsukuba 305-0047, Japan
| | - H Toki
- Graduate School of Engineering Science, Osaka University, 1-3, Machikaneyama-Cho, Toyonaka, Osaka 560-8531, Japan
| |
Collapse
|
2
|
Miyata T, Kumamaru H, Mii S, Kinukawa N, Miyata H, Shigematsu K, Azuma N, Ishida A, Izumi Y, Inoue Y, Uchida H, Ohki T, Kuma S, Kurosawa K, Kodama A, Komai H, Komori K, Shibuya T, Shindo S, Sugimoto I, Deguchi J, Hoshina K, Hideaki M, Midorikawa H, Yamaoka T, Yamashita H, Yunoki Y. Prediction Models for Two Year Overall Survival and Amputation Free Survival After Revascularisation for Chronic Limb Threatening Ischaemia. Eur J Vasc Endovasc Surg 2022; 64:367-376. [PMID: 35680042 DOI: 10.1016/j.ejvs.2022.05.038] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2021] [Revised: 03/27/2022] [Accepted: 05/29/2022] [Indexed: 11/03/2022]
Abstract
OBJECTIVE The aim of this study was to create prediction models for two year overall survival (OS) and amputation free survival (AFS) after revascularisation in patients with chronic limb threatening ischaemia (CLTI). METHODS This was a retrospective analysis of prospectively collected multicentre registry data (JAPAN Critical Limb Ischaemia Database; JCLIMB). Data from 3 505 unique patients with CLTI who had undergone revascularisation from 2013 to 2017 were extracted from the JCLIMB for the analysis. The cohort was randomly divided into development (2 861 patients) and validation cohorts (644 patients). In the development cohort, multivariable risk models were constructed to predict two year OS and AFS using Cox proportional hazard regression analysis. These models were applied to the validation cohort and their performances were evaluated using Harrell's C index and calibration plots. RESULTS Kaplan-Meier estimates of two year OS and AFS post-revascularisation in the whole cohort were 69% and 62%, respectively. Strong predictors for OS consisted of age, activity, malignant neoplasm, chronic kidney disease (CKD), congestive heart failure (CHF), geriatric nutritional risk index (GNRI), and sex. Strong predictors for AFS included age, activity, malignant neoplasm, CKD, CHF, GNRI, body temperature, white blood cells, urgent revascularisation procedure, and sex. Prediction models for two year OS and AFS showed good discrimination with Harrell's C indexes of 0.73 (95% confidence interval [CI] 0.69 - 0.77) and 0.72 (95% CI 0.68 - 0.76), respectively CONCLUSION: Prediction models for two year OS and AFS post-revascularisation in patients with CLTI were created. They can assist in determining treatment strategies and serve as risk adjustment modalities for quality benchmarking for revascularisation in patients with CLTI at each facility.
Collapse
Affiliation(s)
- Tetsuro Miyata
- Office of Medical Education, School of Medicine, International University of Health and Welfare, Chiba, Japan.
| | - Hiraku Kumamaru
- Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Shinsuke Mii
- Department of Vascular Surgery, Saiseikai Yahata General Hospital, Fukuoka, Japan
| | - Naoko Kinukawa
- Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Hiroaki Miyata
- Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Kunihiro Shigematsu
- Department of Vascular Surgery, International University of Health and Welfare, Mita Hospital, Tokyo, Japan
| | - Nobuyoshi Azuma
- Department of Vascular Surgery, Asahikawa Medical University Hospital, Hokkaido, Japan
| | - Atsuhisa Ishida
- Department of Surgery, Kawasaki Medical School General Medical Centre, Okayama, Japan
| | - Yuichi Izumi
- Department of Cardiovascular Surgery, Nayoro City General Hospital, Hokkaido, Japan
| | | | - Hisashi Uchida
- Department of Cardiovascular Surgery, Sapporo Kousei Hospital, Hokkaido, Japan
| | - Takao Ohki
- Department of Vascular Surgery, The Jikei University Hospital, Tokyo, Japan
| | - Sosei Kuma
- Department of Vascular Surgery, Kyushu Central Hospital, Fukuoka, Japan
| | - Koji Kurosawa
- Department of Vascular Surgery, Atsugi City Hospital, Kanagawa, Japan
| | - Akio Kodama
- Division of Vascular and Endovascular Surgery, Department of Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Hiroyoshi Komai
- Department of Vascular Surgery, Kansai Medical University Medical Centre, Osaka, Japan
| | - Kimihiro Komori
- Division of Vascular and Endovascular Surgery, Department of Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Takashi Shibuya
- Department of Cardiovascular Surgery, Osaka University Hospital, Osaka, Japan
| | - Shunya Shindo
- Department of Cardiovascular Surgery, Tokyo Medical University, Hachioji Medical Centre, Tokyo, Japan
| | - Ikuo Sugimoto
- Department of Medical Safety Management, Aichi Medical University, Aichi, Japan
| | - Juno Deguchi
- Department of Vascular Surgery, Saitama Medical Centre, Saitama Medical University, Saitama, Japan
| | - Katsuyuki Hoshina
- Department of Vascular Surgery, The University of Tokyo Hospital, Tokyo, Japan
| | - Maeda Hideaki
- Department of Vascular Surgery, Nihon University Itabashi Hospital, Tokyo, Japan
| | - Hirofumi Midorikawa
- Department of Cardiovascular Surgery, Southern TOHOKU General Hospital, Fukushima, Japan
| | - Terutoshi Yamaoka
- Department of Vascular Surgery, Matsuyama Red Cross Hospital, Ehime, Japan
| | - Hiroya Yamashita
- Department of Vascular Surgery, Kumamoto Rehabilitation Hospital, Kumamoto, Japan
| | - Yasuhiro Yunoki
- Department of Cardiovascular Surgery, Kawasaki Medical School Hospital, Okayama, Japan
| |
Collapse
|
3
|
Nagumo Y, Kimura T, Ishikawa H, Sekino Y, Maruo K, Mathis B, Takemura M, Kageyama Y, Ushijima H, Kawai T, Yamashita H, Azuma H, Naiki T, Kobayashi Y, Inokuchi J, Osawa T, Kita Y, Tsuzuki T, Hashimoto K, Nishiyama H. 1740P Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART): An open-label, single-arm, multicenter, phase II trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Uchida N, Hiraoka K, Sujino T, Yamashita H, Ishikawa T, Kawai K. P-199 Effect of the area of oocyte perivitelline space on the fertilization and embryo development following intracytoplasmic sperm injection. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does the area of oocyte perivitelline space have an effect on fertilization and embryo development following intracytoplasmic sperm injection?
Summary answer
The area of oocyte perivitelline space has not an effect on the fertilization but the embryo development following intracytoplasmic sperm injection.
What is known already
Oocyte perivitelline space has a lot of variation at intracytoplasmic sperm injection (ICSI). Some researchers reported that the characteristics of perivitelline space (large or small) affect embryo development, pregnancy, and implantation. However, these studies did not accurately calculate the area of perivitelline space. Therefore, little information is available on the effect of the area of oocyte perivitelline space on fertilization and embryo development following ICSI. The purpose of this study was to calculate and classify the area of oocyte perivitelline space and investigate the effect of the area of perivitelline space on fertilization and embryo development following ICSI.
Study design, size, duration
1. We retrospectively investigated 634 mature oocytes that were conducted ICSI between January 2021 and December 2021. The area of each oocyte perivitelline space was defined from between the area of circle calculated from the inner layer of zona pellucida and cytoplasm and divided into 3 groups (-9%, 10-19%, 20%-).
2. We retrospectively calculated the diameter of an inner layer of zona pellucida and cytoplasm and compared it with the 3 groups (-9%, 10-19%, 20%-).
Participants/materials, setting, methods
1. The fertilization, survival, good quality day-3 embryo, blastocyst, good quality blastocyst rates following ICSI were compared with the 3 groups (-9%, 10-19%, 20%-).
2. The average diameter of an inner layer of zona pellucida and cytoplasm of each oocyte for the 3 groups (-9%, 10-19%, 20%-) were compared.
The data were analyzed by Fisher’s exact test, residual analysis, one-way ANOVA test, with Bonferroni correction as appropriate to determine the statistical differences among groups.
Main results and the role of chance
1. The survival rates of perivitelline space -9%, 10-19%, 20%- groups were 100% (109/109), 96% (363/378), 94% (138/147), the fertilization rates were 89% (97/109), 88% (331/378), 86% (127/147), the good quality day-3 embryo rates were 56% (54/97), 70% (232/331), 70% (89/127) respectively. No significant difference was observed between these comparison items. The blastocyst rates of perivitelline space -9%, 10-19%, 20%- groups were 51% (47/92), 69% (222/321), 82% (93/114), the good quality blastocyst rates were 22% (20/92), 40% (129/321), 52% (59/114) respectively. The blastocyst and good quality blastocyst rates of perivitelline space -9% group showed significantly lower results. On the other hand, the blastocyst and good quality blastocyst rates of perivitelline space 20%- group showed significantly higher results.
2. The average diameter of an inner layer of zona pellucida of perivitelline space -9%, 10-19%, 20%- groups were 125 ± 4 µm, 129 ± 5 µm, 136 ± 6 µm, the average diameter of the cytoplasm of perivitelline space were 121 ± 4 µm, 119 ± 4 µm, 118 ± 4 µm respectively. Significant differences were observed in all pairs of groups of the average diameter of an inner layer of zona pellucida and cytoplasm.
Limitations, reasons for caution
The area of oocyte perivitelline space was calculated at only one plane.
Wider implications of the findings
Oocytes with narrow perivitelline space might have a wide region of adhesive between the cytoplasm surface and an inner layer of the zona pellucida which resulted in a smaller diameter of the zona pellucida and lower blastocyst rate by forming cytoplasmic fragments (Yumoto K et al. JARG. 2020 ;37(6):1349-1354.).
Trial registration number
Not Applicable
Collapse
Affiliation(s)
- N Uchida
- Kameda IVF Clinic Makuhari, ART Laboratory , Chiba, Japan
| | - K Hiraoka
- Kameda IVF Clinic Makuhari, ART Laboratory , Chiba, Japan
| | - T Sujino
- Kameda IVF Clinic Makuhari, ART Laboratory , Chiba, Japan
| | - H Yamashita
- H.U. Group Research Institute G.K., Research Laboratory , Tokyo, Japan
| | - T Ishikawa
- Tokyo Medical and Dental University, Comprehensive Reproductive Medicine , Tokyo, Japan
| | - K Kawai
- Kameda IVF Clinic Makuhari, ART Laboratory , Chiba, Japan
| |
Collapse
|
5
|
Wada A, Yamashita H, Togashi A, Ogawa S, Muroi A, Kido S, Furuya S. The effect of parenteral amino acid infusion combined with intermittent loading exercise on postoperative sarcopenic rat models. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
6
|
Momoi Y, Tsusaki T, Yamashita H, Takahashi H. The effectiveness of an SNP marker in the cholecystokinin type A receptor gene for improving growth traits in Amakusa Daioh cross chickens. J APPL POULTRY RES 2021. [DOI: 10.1016/j.japr.2021.100166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
7
|
Sakai H, Yamashita H, Nakajima S, Takahashi Y, Kaneko H. AB0391 LOW SERUM COMPLEMENT C3 LEVEL AS A RISK FACTOR FOR RELAPSE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: A RETROSPECTIVE COHORT STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The alternative pathway of complement activation has recently been recognized as a key pathogenic event in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Some previous studies have reported that low serum complement C3 level in AAV patients is associated with more severe renal disease, worse renal prognosis, or higher mortality. However, the correlation between low serum C3 level and AAV relapse remains unclear.Objectives:To analyze the clinical characteristics and outcomes of AAV patients with low serum C3 levels at the time of diagnosis.Methods:We conducted a retrospective observational cohort study including 83 consecutive patients diagnosed with AAV in our hospital from January 1999 to December 2020. Serum C3 levels were measured at diagnosis. AAV included microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA); patients with ANCA-negative AAV were excluded. Patients were divided into low- and high-C3 groups (C3 < 100 and ≥ 100 mg/dL, respectively). We compared the clinical characteristics, and relapse-free and overall survival rates, of the two groups, and identified predictors of AAV relapse.Results:Of the 83 patients (MPA, n = 61; GPA, n = 18; EGPA, n = 4), 20 (24%) were in the low-C3 group. We found no significant group difference in sex, body mass index, disease type, ANCA subtype, Birmingham Vasculitis Activity Score (BVAS), or treatment. The low-C3 group patients were older (p=0.01), and had a higher Five Factor Score (FFS) (p=0.01) and a lower remission rate (p=0.02), than the high-C3 group. The generalized Wilcoxon test revealed that the relapse-free survival time was significantly shorter in the low-C3 group (29 months; 95% confidence interval [CI]: 15–49) than in the high-C3 group (82 months; 95% CI: 61–NA; p=0.01) (Figure 1A). The overall survival was also shorter in the low-C3 group (83 months; 95% CI: 8-121) than in the high-C3 group (112 months; 95% CI: 77-NA; p=0.03) (Figure 1B). In the Cox proportional hazards model, a low C3 level (< 100 mg/dL) (hazard ratio [HR], 3.01; 95% CI: 1.29–7.04], p=0.01) and GPA (HR, 3.04; 95% CI: 1.32–7.01; p=0.01) were independent predictors of AAV relapse.Figure 1.Kaplan-Meier estimates of the relapse-free (A) and overall (B) survival rates of AAV patients by baseline serum C3 levels. Eight patients who did not show remission were excluded in the relapse-free survival analysis. Black line: high-C3 group (≥ 100 mg/dL); red line: low-C3 group (< 100 mg/dL).Conclusion:AAV patients with low C3 levels at diagnosis were at higher risk of relapse. Larger prospective studies are required to confirm these findings.Disclosure of Interests:None declared
Collapse
|
8
|
Ogita M, Nozawa Y, Nawa K, Yamashita H, Nakagawa K. Volumetric Modulated Arc Therapy Versus Three-Dimensional Conformal Radiotherapy for Breast Cancer Patients Treated with Regional Nodal Irradiation. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Yamamoto T, Yuzuru N, Yamada K, Aoki M, Onishi H, Katsui K, Dekura Y, Nishikawa A, Manabe Y, Kubota S, Yamashita H, Jingu K. PO-0990: Prevention of oncologic pulmonary death by control for pulmonary oligometastases treated with SBRT. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01007-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Takahashi M, Shimokawa T, Ko J, Takeshima T, Yamashita H, Kajimoto Y, Mori A, Ito H. Efficacy and safety of istradefylline in Parkinson's disease patients with postural abnormality: results from a multicenter open-label study in Japan. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Sugino T, Okada A, Chaya R, Tanaka Y, Unno R, Taguchi K, Hamamoto S, Ando R, Mogami T, Yamashita H, Yasui T. Brown adipocytes prevent kidney stone formation via heat-producing protein, uncoupling protein 1. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32856-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Izuka S, Yamashita H, Takahashi Y, Kaneko H. SAT0040 RISK FACTORS FOR DEVELOPING AND MORTALITY FOR ACUTE EXACERBATION OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Among collagen vascular diseases, rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is the most commonly associated with ILD with acute exacerbation (AE) [1]. One study reported that ILD diagnosis at an older age, the usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography, and methotrexate (MTX) use were associated with AE in patients with RA-ILD [2]. However, because these studies included few patients, the risk factors and prognosis of AE in patients with RA-ILD remain unclear. Therefore, this study examined the characteristics of RA-ILD patients with AE, and the variables associated with mortality due to AE of RA-ILD.Objectives:To investigate the risk factors for AE and mortality of RA-ILD.Methods:We retrospectively collected the clinical data of 165 RA-ILD patients admitted to our hospital between July 2010 and October 2019. We compared clinical characteristics between patients who developed AE (AE group) and those who did not (non-AE group), and identified the variables significantly associated with AE occurrence. We also compared the admission characteristics of those who survived (survivor group) and those who died (non-survivor group) after admission for AE. AE was defined using previously proposed criteria [3], which were modified slightly for application to RA-ILD.Results:The mean patient age was 73.6 ± 9.7 years and 97 (71.9%) patients were female. Thirty (22.2%) patients developed AE, of whom thirteen (43.3%) died (mean follow-up, 64.9 months). In univariate analyses UIP pattern and MTX were not associated with AE. However, in multivariate analyses, UIP pattern was associated with AE (OR 2.68, 95% CI 1.10–6.52,p=0.03). Median age (70vs. 80 years,p=0.003), non-use of MTX (70.6%vs. 23.1%,p=0.025), and C reactive protein level (median 9.38vs. 18.12 mg/dL,p=0.02) on admission were significantly higher in patients who died of AE. In the Cox proportional hazard model, UIP pattern (HR 4.67, 95% CI 1.02–21.5,p=0.048) and non-use of MTX (HR 0.16, 95% CI 0.04–0.72,p=0.016) were associated with death.Conclusion:Our data suggest that the UIP pattern is related to AE, and non-use of MTX and UIP pattern are related to death due to AE of RA-ILD.References:[1] Suda T, Kaida Y, Nakamura Y et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases.Respir Med2009;103:846-53.[2] Hozumi H, Nakamura Y, Johkoh T et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study.BMJ Open2013;3:e003132.[3] Collard HR, Moore BB, Flaherty KR et al. Idiopathic pulmonary fibrosis clinical research network investigators. Acute exacerbations of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2007;176:636-43.Disclosure of Interests:None declared
Collapse
|
13
|
Abstract
Transposable element (TE) marker system was developed considering the useful properties of the transposable elements such as their large number in the animal and plant genomes, high rate of insertion polymorphism, and ease of detection. Various methods have been employed for developing a large number of TE markers in several crop plants for genomics studies. Here we describe some of these methods including the recent whole genome search. We also review the application of TE markers in molecular breeding.
Collapse
Affiliation(s)
- R S Bhat
- Department of Biotechnology, University of Agricultural Sciences, Dharwad, Karnataka, India.
| | - K Shirasawa
- Department of Frontier Research and Development, Kazusa DNA Research Institute, Chiba, Japan
| | - Y Monden
- Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan
| | - H Yamashita
- Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan
| | - M Tahara
- Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan
| |
Collapse
|
14
|
Takaesu Y, Utsumi T, Okajima I, Shimura A, Kotorii N, Kuriyama K, Yamashita H, Suzuki M, Watanabe N, Mishima K. Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: a systematic review and meta-analysis. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.1036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Onishi H, Shioyama Y, Matsuo Y, Takayama K, Miyakawa A, Yamashita H, Nomiya T, Matsumo Y, Matsushita H, Kimura T, Murakami N, Ishiyama H, Uno T, Takanaka T, Katoh N, Takeda A, Nakata K, Ogawa K, Nihei K, Aoki M, Kuriyama K, Komiyama T, Marino K, Araya M, Aoki S, Saito R, Maehata Y, Tominaga R, Nonaka H, Oguri M, Matsuda M, Yamada T, Akita T, Hiraoka M. Prognosis after Local Recurrence or Metastases in Medically Operable Stage I Non-Small Cell Lung Cancer Patients Treated By Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Nakano M, Kubo K, Shirota Y, Iwasaki Y, Takahashi Y, Igari T, Inaba Y, Takeshima Y, Tateishi S, Yamashita H, Miyazaki M, Sato H, Kanda H, Kaneko H, Ishii T, Fujio K, Tanaka N, Mimori A. Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan. Lupus 2019; 28:1062-1073. [PMID: 31296139 PMCID: PMC6681441 DOI: 10.1177/0961203319860200] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Objective The objective of this study was to investigate possible differences in
treatment responses between two categories for the onset of lupus
nephritis. Methods We performed a multicentre, retrospective cohort study of class III–V lupus
nephritis patients diagnosed between 1997 and 2014. The renal responses to
initial induction therapy were compared between patients who developed lupus
nephritis within one year from diagnosis of systemic lupus erythematosus
(early (E-) LN) and the remainder (delayed (D-) LN) using the Kaplan–Meier
method. We determined the predictors of renal response as well as renal
flares and long-term renal outcomes using multivariate Cox regression
analyses. Results A total of 107 E-LN and 70 D-LN patients were followed up for a median of
10.2 years. Log-rank tests showed a lower cumulative incidence of complete
response in D-LN compared with E-LN patients. Multivariate analysis
identified D-LN (hazard ratio (HR) 0.48, 95% confidence interval (CI)
0.33–0.70), nephrotic syndrome at baseline, and a chronicity index greater
than 2 as negative predictors of complete response. D-LN patients were more
likely to experience renal flares. D-LN (HR 2.54, 95% CI 1.10–5.83) and
decreased renal function were significant predictors of chronic kidney
disease at baseline. Conclusion D-LN was a predictor of poorer treatment outcomes, in addition to renal
histology and severity of nephritis at lupus nephritis onset.
Collapse
Affiliation(s)
- M Nakano
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan.,2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - K Kubo
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Shirota
- 3 Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Y Iwasaki
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Y Takahashi
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Igari
- 4 Pathology Division of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Inaba
- 5 Biostatistics Section, Department of Clinical Research and Informatics, Clinical Science Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Takeshima
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,6 Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - S Tateishi
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,7 Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - H Yamashita
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Miyazaki
- 8 Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - H Sato
- 9 Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan
| | - H Kanda
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,7 Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - H Kaneko
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Ishii
- 3 Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.,10 Clinical Research, Innovation and Educational Center, Tohoku University Hospital, Sendai, Japan
| | - K Fujio
- 2 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - N Tanaka
- 5 Biostatistics Section, Department of Clinical Research and Informatics, Clinical Science Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - A Mimori
- 1 Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
17
|
KITAMURA M, Hidaka M, Inoue Y, Muta K, Ota Y, Yamashita H, Yoko O, Eguchi S, Nishino T. SAT-274 PRE-TRANSPLANT RENAL FUNCTION PREDICTS TRANSPLANTED LIVER PROGNOSES IN LIVING DONER LIVER TRANSPLANTATION. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
18
|
Tanioka H, Nagasaka T, Uno F, Inoue M, Okita H, Katata Y, Kanzaki H, Kuramochi H, Satake H, Shindo Y, Doi A, Nasu J, Yamashita H, Yamaguchi Y. Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Kiritoshi T, Yamashita H, Takahashi W, Ogita M, Nakagawa K, Abe O. EP-1419 Salvage concurrent chemoradiotherapy for postoperative locoregional recurrence of esophageal cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31839-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Sugawara K, Mori K, Yagi K, Aikou S, Uemura Y, Yamashita H, Seto Y. Association of preoperative inflammation-based prognostic score with survival in patients undergoing salvage esophagectomy. Dis Esophagus 2019; 32:5060212. [PMID: 30535140 DOI: 10.1093/dote/doy066] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Salvage esophagectomy (SALV) is potentially beneficial for patients with residual or relapsed esophageal carcinoma after definitive chemoradiotherapy (dCRT), although preoperatively identifying good candidates for SALV remains difficult. We investigated the prognostic impacts of inflammatory and nutritional status in patients undergoing SALV after dCRT. Forty-seven SALV patients were retrospectively reviewed, of whom 46 (98%) had squamous cell carcinoma and 1 (2%) adenocarcinoma. Possible prognostic factors included patients' demographic data, physical status, blood chemistry profiles, and clinical/pathological tumor features. The Glasgow prognostic score (GPS) was derived from preoperative C-reactive protein (CRP) and albumin values. Thirty (64%), 11 (23%), and 6 (13%) patients were classified into the GPS 0, 1, and 2, respectively, groups. None of the possible prognostic factors showed significant correlations with GPS. Patients with GPS 0 had better outcomes than those with GPS 1 or GPS 2 (Median survivals: 37.8, 15.9, and 5.1 months, respectively, P < 0.001). In the multivariable Cox proportional hazards model, GPS 1 (HR 5.62, 95% CI 1.94-16.4, P = 0.002), GPS 2 (HR 9.10, 95% CI 2.60-31.8, P < 0.001), R1/2 resection (HR 16.3, 95% CI 3.62-86.7, P < 0.001) and incomplete response to dCRT (HR 3.53, 95% CI 1.12-12.5, P = 0.03) were all independent risk factors for a poor outcome. Preoperative GPS is potentially useful for predicting outcomes in esophageal cancer patients undergoing SALV.
Collapse
Affiliation(s)
- K Sugawara
- Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo
| | - K Mori
- Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo.,Department of Gastrointestinal Surgery, Mitsui Memorial Hospital, Tokyo, Japan
| | - K Yagi
- Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo
| | - S Aikou
- Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo
| | - Y Uemura
- Biostatistics Division, Clinical Research Support Center, Graduate School of Medicine, the University of Tokyo
| | - H Yamashita
- Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo
| | - Y Seto
- Department of Gastrointestinal Surgery, Graduate School of Medicine, the University of Tokyo
| |
Collapse
|
21
|
Aoki S, Yamashita H, Takahashi W, Nawa K, Ota T, Nozawa Y, Ozaki S, Nakamoto T, Nakagawa K. EP-1360 Salvage SBRT for postoperative recurrence of NSCLC. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31780-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
22
|
Onishi H, Imai T, Ito Y, Matsumo Y, Onimaru R, Shioyama Y, Yoshitake T, Kokubo M, Takayama K, Yamashita H, Matsuo Y, Matsushita H, Karasawa K, Kuriyama K, Komiyama T, Shirato H. Single Nucleotide Polymorphisms of Inflammation-Related Genes As Predictive Risk Factors of Radiation Pneumonitis after Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Hosokawa A, Yamazaki K, Matsuda C, Ueda S, Fujii H, Baba E, Okamura S, Tsuda M, Tamura T, Shinozaki K, Tsushima T, Tsuda T, Shirakawa T, Yamashita H, Morita S, Muro K. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Kaneoka A, Yang S, Inokuchi H, Ueha R, Yamashita H, Nito T, Seto Y, Haga N. Presentation of oropharyngeal dysphagia and rehabilitative intervention following esophagectomy: a systematic review. Dis Esophagus 2018; 31:5000038. [PMID: 29788321 PMCID: PMC6127108 DOI: 10.1093/dote/doy050] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
No study has systematically reviewed the evidence on presentation of oropharyngeal dysphagia and swallowing rehabilitation following esophagectomy. The purposes of this systematic review are to 1) qualitatively synthesize the current findings on oropharyngeal swallowing abnormalities identified by instrumental swallowing evaluations, 2) describe the reported health-related outcomes in relation to swallowing abnormality following esophagectomy, and 3) examine the efficacy of reported rehabilitative interventions for oropharyngeal dysphagia in patients who underwent esophagectomy. Publications were searched using five electronic databases. No language or publication date restrictions were imposed. Two authors performed a blind review for published or unpublished studies that reported swallowing biomechanics and dysphagic symptoms using instrumental evaluation of swallowing, specifically the videofluoroscopic swallowing study and fiberoptic endoscopic evaluation of swallowing, and/or health-related outcomes in relation to swallowing abnormalities, and/or therapeutic interventions for oropharyngeal dysphagia following esophagectomy. Twelve studies out of 2,193 studies including 458 patients met the inclusion criteria. Reported abnormal swallowing biomechanics included vocal fold immobility, delayed onset of swallowing, reduced hyolaryngeal elevation, and reduced opening of the upper esophageal sphincter. Aspiration (0-81%) and pharyngeal residue (22-100%) were prevalent. Those abnormal swallowing biomechanics and swallowing symptoms were commonly reported following both transhiatal and transthoracic esophagectomy. Pneumonia presented in 5-25% of the study patients. One quasi-experimental study examined the effectiveness of swallowing exercises for postoperative oropharyngeal dysphagia; three case series reported a benefit of the chin-tuck maneuver in reducing aspiration and residue. This review revealed distinct swallowing impairments and increased pneumonia risks following esophagectomy. This review also found that evidence on the efficacy of therapeutic interventions was limited. Future studies are warranted to develop effective rehabilitative interventions for postesophagectomy patients with oropharyngeal dysphagia.
Collapse
Affiliation(s)
- A Kaneoka
- Rehabilitation Center, The University of Tokyo Hospital
| | - S Yang
- Department of Otolaryngology Head and Neck Surgery, The University of California, San Francisco, California, USA
| | - H Inokuchi
- Rehabilitation Center, The University of Tokyo Hospital
| | - R Ueha
- Department of Otorhinolaryngology and Head and Neck Surgery
| | - H Yamashita
- Department of Gastrointestinal Surgery, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - T Nito
- Department of Otorhinolaryngology and Head and Neck Surgery
| | - Y Seto
- Department of Gastrointestinal Surgery, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - N Haga
- Rehabilitation Center, The University of Tokyo Hospital
| |
Collapse
|
25
|
Sasaki N, Ozono R, Fujiwara S, Yamashita H, Yamamoto H, Kihara Y. P2541Poor sleep is associated with serum N-terminal pro-brain natriuretic peptide level in elderly people. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- N Sasaki
- Hiroshima Atomic Bomb Casualty Council, Health Management and Promotion Center, Hiroshima, Japan
| | - R Ozono
- Ozono Clinic Internal Medicine & Cardiology, Mihara, Japan
| | - S Fujiwara
- Hiroshima Atomic Bomb Casualty Council, Health Management and Promotion Center, Hiroshima, Japan
| | - H Yamashita
- Hiroshima University Graduate School of Biomedical and Health Sciences, Department of Psychiatry and Neurosciences, Hiroshima, Japan
| | - H Yamamoto
- Hiroshima University Graduate School of Biomedical and Health Sciences, Department of Cardiovascular Medicine, Hiroshima, Japan
| | - Y Kihara
- Hiroshima University Graduate School of Biomedical and Health Sciences, Department of Cardiovascular Medicine, Hiroshima, Japan
| |
Collapse
|
26
|
Sasaki N, Ozono R, Yamashita H, Teramen K, Kihara Y. P4386Chronotype and diabetes in middle-aged and elderly people: Importance of mismatch between chronotype and actual lifestyle. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- N Sasaki
- Hiroshima Atomic Bomb Casualty Council, Health Management and Promotion Center, Hiroshima, Japan
| | - R Ozono
- Ozono Clinic Internal Medicine & Cardiology, Mihara, Japan
| | - H Yamashita
- Hiroshima University Graduate School of Biomedical and Health Sciences, Department of Psychiatry and Neurosciences, Hiroshima, Japan
| | - K Teramen
- Mitsubishi Mihara Hospital, Department of Internal Medicine, Mihara, Japan
| | - Y Kihara
- Hiroshima University Graduate School of Biomedical and Health Sciences, Department of Cardiovascular Medicine, Hiroshima, Japan
| |
Collapse
|
27
|
Yoshino A, Okamoto Y, Okada G, Takamura M, Ichikawa N, Shibasaki C, Yokoyama S, Doi M, Jinnin R, Yamashita H, Horikoshi M, Yamawaki S. Changes in resting-state brain networks after cognitive-behavioral therapy for chronic pain. Psychol Med 2018; 48:1148-1156. [PMID: 28893330 DOI: 10.1017/s0033291717002598] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Cognitive-behavioral therapy (CBT) is thought to be useful for chronic pain, with the pathology of the latter being closely associated with cognitive-emotional components. However, there are few resting-state functional magnetic resonance imaging (R-fMRI) studies. We used the independent component analysis method to examine neural changes after CBT and to assess whether brain regions predict treatment response. METHODS We performed R-fMRI on a group of 29 chronic pain (somatoform pain disorder) patients and 30 age-matched healthy controls (T1). Patients were enrolled in a weekly 12-session group CBT (T2). We assessed selected regions of interest that exhibited differences in intrinsic connectivity network (ICN) connectivity strength between the patients and controls at T1, and compared T1 and T2. We also examined the correlations between treatment effects and rs-fMRI data. RESULTS Abnormal ICN connectivity of the orbitofrontal cortex (OFC) and inferior parietal lobule within the dorsal attention network (DAN) and of the paracentral lobule within the sensorimotor network in patients with chronic pain normalized after CBT. Higher ICN connectivity strength in the OFC indicated greater improvements in pain intensity. Furthermore, ICN connectivity strength in the dorsal posterior cingulate cortex (PCC) within the DAN at T1 was negatively correlated with CBT-related clinical improvements. CONCLUSIONS We conclude that the OFC is crucial for CBT-related improvement of pain intensity, and that the dorsal PCC activation at pretreatment also plays an important role in improvement of clinical symptoms via CBT.
Collapse
Affiliation(s)
- A Yoshino
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - Y Okamoto
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - G Okada
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - M Takamura
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - N Ichikawa
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - C Shibasaki
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - S Yokoyama
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - M Doi
- Department of Dental Anesthesiology,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - R Jinnin
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - H Yamashita
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| | - M Horikoshi
- National Center for Cognitive Behavior Therapy and Research,National Center of Neurology and Psychiatry (NCNP),4-1-1, Ogawahigashicho,Kodaira,Tokyo 187-0031,Japan
| | - S Yamawaki
- Department of Psychiatry and Neurosciences,Division of Frontier Graduate School of Biomedical Sciences,Hiroshima University,1-2-3 Kasumi,Minami-ku,Hiroshima 734-8551,Japan
| |
Collapse
|
28
|
Noshita Y, Sato K, Yamashita H, Kasada R, Xu Q, Hatakeyama M, Sunada S. Detection of phase separation of neutron-irradiated Fe–Cr binary alloys using positron annihilation spectroscopy. Nuclear Materials and Energy 2018. [DOI: 10.1016/j.nme.2018.04.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Takahashi W, Nomoto A, Okuma K, Sawayanagi S, Yamashita H, Nakagawa K. EP-1211: High-dose vs conventional radiotherapy for high-grade glioma: A propensity score-matched analysis. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31521-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
30
|
Ogita M, Yamamoto K, Shiraishi K, Sawayanagi S, Yamashita H, Nakagawa K. PO-0827: Five year follow-up of prostate cancer patients treated with volumetric modulated arc therapy (VMAT). Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31137-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Smyth LM, Oliveira M, Ciruelos E, Tamura K, El-Khoueiry A, Mita A, You B, Renouf DJ, Sablin MP, Lluch A, Mayer IA, Bando H, Yamashita H, Ambrose H, de Bruin E, Carr TH, Corcoran C, Foxley A, Lindemann JPO, Maudsley R, Pass M, Rutkowski A, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Abstract P5-21-32: AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: E17K is the most common activating AKT1 mutation and was shown to be a therapeutic target in this multipart Phase 1 study of AZD5363 (NCT01226316), an oral and selective pan-AKT kinase inhibitor, in patients (pts) with AKT1-mutant (AKT1m) advanced solid tumors. In heavily pretreated AKT1m (E17K) ER+ metastatic breast cancer (MBC) pts, monotherapy achieved an objective response rate (ORR) of 20% and a median progression-free survival of 5.5 months (95% CI, 2.9−6.9). Suppression of PI3K-AKT signaling results in induction of ER-dependent transcription, potentially limiting the response to single-agent PI3K/AKT inhibitors. We explored the hypothesis that simultaneous inhibition of AKT and ER signaling would enhance antitumor efficacy in AKT1m ER+ MBC.
Methods: In an expansion of this study, we administered oral AZD5363 400 mg twice daily, 4 days on 3 days off, and fulvestrant 500 mg, to AKT1m (detected in tumor tissue by local screening and/or plasma BEAMing) ER+ HER2– MBC pts, enrolled into a fulvestrant-naïve (FN) or fulvestrant-resistant (FR) cohort (max 24 pts/cohort). Key objectives included safety and efficacy by RECIST v1.1. We report results of a planned interim analysis conducted when 12 pts/cohort reached maturity for assessment of 24-week clinical benefit rate (CBR), defined as the percentage of responders plus those with stable disease (SD) ≥24 weeks.Data cut-off occurred in June 2017.
Results: At the time of analysis, 24 AKT1m pts (23 E17K, 1 E40K) had received treatment. FN had more visceral disease (83.3% vs 66.7%) and ER+/PR– status (25% vs 8.3%) than FR. Median number of prior anticancer regimens was 4.5 (range 1–9) and 6 (2–11) in FN and FR, respectively, with more chemotherapy (CT) and less hormone therapy (HT) exposure in FN vs FR [3 (0–5) vs 2 (0–6) and 2 (0–4) vs 4 (2–6) prior CT and HT, respectively]. Prior palbociclib was received by 1 (8.3%) and 4 (33.3%) pts in FN and FR, respectively. Clinical efficacy is detailed below; CBR was 33% and 42% in FN and FR, respectively (Table 1). There was 1 unconfirmed partial response in patients treated with prior palbociclib and 3 SD. At data cut-off, 18 pts had discontinued treatment: progressive disease, n=12; adverse events (AEs), n=2; other reasons, n=4. AEs were observed in all 24 pts, most commonly diarrhea (71%), nausea (63%), vomiting and decreased appetite (29%). Grade ≥3 AEs occurred in 13 (54%) pts, most frequently maculopapular rash (n=3), nausea, hyperglycemia and back pain (all n=2). Dose reduction due to AEs occurred in 3 pts.
Table 1. Clinical efficacy FNFREligible for interim data cut-off, n1212ORR, n (%)2 (17)4 (33)CBR, n (%)4 (33)5 (42)Confirmed response (complete/partial response), n (%)2 (17)4 (33)SD ≥24 weeks, n (%)2 (17)1 (8)
Conclusions: AZD5363 plus fulvestrant is clinically active in AKT1m ER+ MBC pts, including in pts with demonstrated prior resistance to fulvestrant. Comparatively lower efficacy was observed in the FN cohort; factors that may have potentially contributed (eg disease characteristics) will be explored. cfDNA and genomic data will also be presented.
Citation Format: Smyth LM, Oliveira M, Ciruelos E, Tamura K, El-Khoueiry A, Mita A, You B, Renouf DJ, Sablin M-P, Lluch A, Mayer IA, Bando H, Yamashita H, Ambrose H, de Bruin E, Carr TH, Corcoran C, Foxley A, Lindemann JPO, Maudsley R, Pass M, Rutkowski A, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-32.
Collapse
Affiliation(s)
- LM Smyth
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Oliveira
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - E Ciruelos
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - K Tamura
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A El-Khoueiry
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Mita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - B You
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - DJ Renouf
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M-P Sablin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Lluch
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - IA Mayer
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - H Bando
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - H Yamashita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - H Ambrose
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - E de Bruin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - TH Carr
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - C Corcoran
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Foxley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - JPO Lindemann
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - R Maudsley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Pass
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Rutkowski
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - G Schiavon
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - U Banerji
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Scaltriti
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - BS Taylor
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Chandarlapaty
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - DM Hyman
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; Hospital Clínico Universitario; INCLIVA Health Research Institute; University of Valencia; CIBERONC-ISCIII, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
32
|
Smyth LM, Oliveira M, Ciruelos E, Tamura K, El-Khoueiry A, Mita A, You B, Renouf DJ, Sablin MP, Lluch A, Mayer IA, Bando H, Yamashita H, Ambrose H, de Bruin E, Carr TH, Corcoran C, Foxley A, Lindemann JPO, Maudsley R, Pass M, Rutkowski A, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Abstract P5-21-05: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- LM Smyth
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M Oliveira
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - E Ciruelos
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - K Tamura
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A El-Khoueiry
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Mita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - B You
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - DJ Renouf
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M-P Sablin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Lluch
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - IA Mayer
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - H Bando
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - H Yamashita
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - H Ambrose
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - E de Bruin
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - TH Carr
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - C Corcoran
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Foxley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - JPO Lindemann
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - R Maudsley
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M Pass
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - A Rutkowski
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - G Schiavon
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - U Banerji
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - M Scaltriti
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - BS Taylor
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - S Chandarlapaty
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| | - DM Hyman
- Memorial Sloan Kettering Cancer Center, New York, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; National Cancer Center Hospital, Tokyo, Japan; University of Southern California, Los Angeles, CA; Cedars-Sinai Medical Center, Los Angeles, CA; British Columbia Cancer Agency, Vancouver, Canada; Institut Curie, Paris and Saint-Cloud, France; University of Valencia, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, CIBERONC, Valencia, Spain; Vanderbilt Breast Center, Nashville, TN; National Cancer Center Hospital East, Chiba, Japan; Hokkaido University Hospital, Sapporo, Japan; AstraZeneca, Cambridge, United Kingdom; Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France
| |
Collapse
|
33
|
Ishida N, Hatanaka Y, Baba M, Hagio K, Okada H, Hatanaka KC, Matsuno Y, Yamashita H. Abstract P4-08-07: PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive, HER2-negative early breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Endocrine therapy is the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. We recently reported that approximately two-thirds of patients who relapsed within 5 years had received anthracyclins and/or taxanes as adjuvant or neoadjuvant chemotherapy in addition to adjuvant endocrine therapy. New strategies, such as signal transduction inhibitors together with endocrine therapy are required to improve survival. PIK3CA mutations are detected in almost 40% of early ER-positive breast cancers, and are therefore the most frequent genetic alterations in this subtype. PIK3CA mutation status is reported to affect activation of AKT and ERα. Moreover, recent studies demonstrate that patients had a better prognosis when tumors expressed ER, androgen receptor (AR), and vitamin D receptor (VDR).
Methods: Expression of AR and VDR, phosphorylation of AKT serine (Ser) 473 (AKT phospho-Ser473) and ERα Ser167 (ERα phospho-Ser167) were examined by immunohistochemistry in ER-positive, HER2-negative early breast cancer tissues. Seventeen mutations in exons 1, 4, 7, 9, and 20 of the PIK3CA gene were detected in genomic DNA extracted from formalin-fixed paraffin-embedded tumor blocks. Correlations between these biological markers and clinicopathological factors and prognosis were analyzed separately in pre- and postmenopausal women.
Results: Levels of AKT phospho-Ser473 were significantly higher in premenopausal women (n = 62) than in postmenopausal women (n = 152) (P < 0.0001 and P = 0.014, respectively). In contrast, expression levels of AR were significantly higher in postmenopausal women than in premenopausal women (P < 0.0001). In premenopausal women, 26 tumors (43%) had a single mutation of PIK3CA gene, and 3 tumors (5%) had mutations at two sites. In postmenopausal women, 64 tumors (44%) had a single PIK3CA mutation, 6 tumors (4%) had mutations at two sites, and one tumor (1%) had mutations at three sites. In premenopausal women, wild type PIK3CA was associated with smaller tumor size, higher ER expression levels, and lower AR expression levels when compared with women in the same cohort with PIK3CA mutant tumors. In postmenopausal women, patients with PIK3CA wild-type tumors had higher Ki67 labeling index, higher AKT phospho-Ser473, and lower ERα phospho-Ser167 when compared to patients with PIK3CA mutant tumors. Postmenopausal women with PIK3CA wild-type tumors had significantly worse disease-free survival than patients with PIK3CA mutant tumors (P = 0.007). In contrast, PIK3CA mutation status was not correlated with survival in premenopausal women. Low levels of AKT phospho-Ser473 and high levels of ERα phospho-Ser167 were strongly associated with increased disease-free survival in postmenopausal women (P = 0.016 and P = 0.0016, respectively).
Conclusion: ERα activation, in addition to PIK3CA mutation, may be biomarkers for highly endocrine-responsive tumors. This would facilitate the selection of postmenopausal ER-positive breast cancer patients who are likely to benefit from endocrine therapy alone from those who are not.
Citation Format: Ishida N, Hatanaka Y, Baba M, Hagio K, Okada H, Hatanaka KC, Matsuno Y, Yamashita H. PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive, HER2-negative early breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-08-07.
Collapse
Affiliation(s)
- N Ishida
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - Y Hatanaka
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - M Baba
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - K Hagio
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - H Okada
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - KC Hatanaka
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - Y Matsuno
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - H Yamashita
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| |
Collapse
|
34
|
Sami M, Yamashita H, Kadokura H, Kitamoto K, Yoda K, Yamasaki M. A New and Rapid Method for Determination of Beer-Spoilage Ability of Lactobacilli. Journal of the American Society of Brewing Chemists 2018. [DOI: 10.1094/asbcj-55-0137] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Manabu Sami
- Brewing Research and Development Laboratory, Asahl Breweries, Ltd., 2-13-1 Ohmori-kita, Ohta-ku, Tokyo 143, Japan
| | - H. Yamashita
- Brewing Research and Development Laboratory, Asahl Breweries, Ltd., 2-13-1 Ohmori-kita, Ohta-ku, Tokyo 143, Japan
| | - H. Kadokura
- Department of Biotechnology, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113, Japan
| | - K. Kitamoto
- Department of Biotechnology, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113, Japan
| | - K. Yoda
- Department of Biotechnology, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113, Japan
| | - M. Yamasaki
- Department of Food Science and Technology, Nihon University, Shimouma 3-34-1, Setagaya-ku, Tokyo 154, Japan
| |
Collapse
|
35
|
Omote M, Harayama K, Sasaki T, Mochizuki N, Yamashita H. Analysis of Simultaneous Screening for 277 Pesticides in Malt and Beer by Liquid Chromatography with Tandem Mass Spectrometry. Journal of the American Society of Brewing Chemists 2018. [DOI: 10.1094/asbcj-64-0139] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- M. Omote
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-chome, Moriya-shi, Ibaraki, Japan
| | - K. Harayama
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-chome, Moriya-shi, Ibaraki, Japan
| | - T. Sasaki
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-chome, Moriya-shi, Ibaraki, Japan
| | - N. Mochizuki
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-chome, Moriya-shi, Ibaraki, Japan
| | - H. Yamashita
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-chome, Moriya-shi, Ibaraki, Japan
| |
Collapse
|
36
|
Suga K, Mochizuki N, Harayama K, Yamashita H. Analysis of Trichothecenes in Malt and Beer by Liquid Chromatography Tandem Mass Spectrometry. Journal of the American Society of Brewing Chemists 2018. [DOI: 10.1094/asbcj-63-0001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- K. Suga
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-Chome, Moriya-shi, Ibaraki, Japan
| | - N. Mochizuki
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-Chome, Moriya-shi, Ibaraki, Japan
| | - K. Harayama
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-Chome, Moriya-shi, Ibaraki, Japan
| | - H. Yamashita
- Analytical Technology Laboratory, Asahi Breweries Ltd., 1-21 Midori 1-Chome, Moriya-shi, Ibaraki, Japan
| |
Collapse
|
37
|
Yuki M, Miyake A, Nakatsumi H, Hirayama K, Ishioka A, Yamashita H, Komatsu Y. Family exposure to cyclophosphamide during outpatient treatment. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx668.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Niibe Y, Yamamoto T, Onishi H, Yamashita H, Katsui K, Matsumoto Y, Oh R, Aoki M, Shintani T, Myojin M, Yamada K, Kobayashi M, Ozaki M, Manabe Y, Yahara K, Nishikawa A, Kakuhara H, Matsuoka Y, Yamamoto K, Fukuda T, Ushijima Y, Ohashi S, Kan T, Kubota S, Inoue T, Yamaguchi N, Takada Y, Nagata K, Suzuki O, Shirai K, Terahara A, Jingu K. MA 09.06 Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy (SBRT): A Nationwide Survey of 1,378 Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Niibe Y, Yamamoto T, Onishi H, Yamashita H, Katsui K, Matsumo Y, Oh R, Aoki M, Shintani T, Myojin M, Yamada K, Kobayashi M, Ozaki M, Manabe Y, Yahara K, Nishikawa A, Kakuhara H, Matuoka Y, Terahara A, Jingu K. Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Multi-institutional Study of 1,378 Subjects. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Takahashi W, Aoki S, Yamashita H, Ogita M, Nakagawa K, Haga A. CT-Based Radiomics Histology Analysis of Stereotactic Ablative Radiation Therapy Patients with Early-Stage Non–small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.2349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Gastrectomy after response to intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Kawaguchi H, Aogi K, Masuda N, Nakayama T, Ito Y, Ohtani S, Sato N, Takano T, Saji S, Tokunaga E, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Sasaki N, Ozono R, Teramen K, Yamashita H, Fujiwara S, Kihara Y. P6215Poor sleep and cardiovascular disease: different pattern of sleep disturbance in ischemic heart disease and stroke. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Yamada S, Yamashita H, Taira K, Hida A, Arai N, Shimizu J, Miyaji Y, Sonoo M, Yashima A, Takahashi Y, Kaneko H. A case of inclusion body myositis complicated by microscopic polyangiitis. Scand J Rheumatol 2017; 47:243-245. [PMID: 28726537 DOI: 10.1080/03009742.2017.1334815] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- S Yamada
- a Division of Rheumatic Diseases , National Center for Global Health and Medicine , Tokyo , Japan
| | - H Yamashita
- a Division of Rheumatic Diseases , National Center for Global Health and Medicine , Tokyo , Japan
| | - K Taira
- b Department of Neurology, Graduate School of Medicine , The University of Tokyo , Tokyo , Japan
| | - A Hida
- c Division of Neurology , National Center for Global Health and Medicine , Tokyo , Japan
| | - N Arai
- c Division of Neurology , National Center for Global Health and Medicine , Tokyo , Japan
| | - J Shimizu
- b Department of Neurology, Graduate School of Medicine , The University of Tokyo , Tokyo , Japan
| | - Y Miyaji
- d Department of Neurology , Teikyo University School of Medicine , Tokyo , Japan
| | - M Sonoo
- d Department of Neurology , Teikyo University School of Medicine , Tokyo , Japan
| | - A Yashima
- a Division of Rheumatic Diseases , National Center for Global Health and Medicine , Tokyo , Japan
| | - Y Takahashi
- a Division of Rheumatic Diseases , National Center for Global Health and Medicine , Tokyo , Japan
| | - H Kaneko
- a Division of Rheumatic Diseases , National Center for Global Health and Medicine , Tokyo , Japan
| |
Collapse
|
45
|
Tanaka S, Kawasaki R, Tanaka-Mizuno S, Iimuro S, Matsunaga S, Moriya T, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Sone H, Yamashita H. Severe hypoglycaemia is a major predictor of incident diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Metab 2017; 43:424-429. [PMID: 28720342 DOI: 10.1016/j.diabet.2017.06.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2017] [Revised: 06/14/2017] [Accepted: 06/14/2017] [Indexed: 12/16/2022]
Abstract
AIM Hypoglycaemia is a common complication in diabetes patients. However, its relationship with retinopathy has not been well documented in patients with type 2 diabetes (T2D). This study aimed to investigate the associations between hypoglycaemia and the incidence and progression of diabetic retinopathy (DR). METHODS In this longitudinal cohort study, which was part of the Japan Diabetes Complications Study (JDCS), adult patients with T2D were recruited at 59 diabetes clinics across Japan. Their history of hypoglycaemia was assessed by standardized self-reported questionnaires. Severe hypoglycaemia was defined as having at least one episode with coma requiring an outpatients visit or hospitalization. Adjusted hazard ratios (HRs) for incidence and progression of DR over 8 years of follow-up were determined. RESULTS Of 1221 patients without DR, 127 (10.4%) had experienced non-severe hypoglycaemia within the previous year, whereas 10 (0.8%) reported severe hypoglycaemia episodes. During the 8-year follow-up involving 8492 person-years, 329 patients developed DR. In 410 patients with prevalent DR, the adjusted HRs for incident DR were 4.35 (95% CI: 1.98-9.56; P<0.01) and, for progression of DR, 2.29 (95% CI: 0.45-11.78; P=0.32) with severe hypoglycaemia. CONCLUSION Having a history of severe hypoglycaemia was one of the strongest predictors of incident DR in patients with T2D, with a fourfold increased risk. Identifying patients with greater risks of DR based on their history of hypoglycaemia may help to personalize risk evaluation in patients with diabetes.
Collapse
Affiliation(s)
- S Tanaka
- Department of pharmacoepidemiology, graduate longitudinal school of medicine and public health, Kyoto university, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, Japan
| | - R Kawasaki
- Department of public health, Yamagata university graduate school of medical science, 2-2-2 Iida-Nishi, Yamagata, Japan.
| | - S Tanaka-Mizuno
- Division of medical statistics, Shiga university of medical science, Tsukinowa Seta-cho, Ohtsu, Shiga, Japan
| | - S Iimuro
- Teikyo academic research centre, Teikyo university, Kaga, Itabashi-ku, Tokyo, Japan
| | - S Matsunaga
- Department of haematology, endocrinology and metabolism, faculty of medicine, Niigata university, 1-757 Asahi-machi, Chuo-ku, Niigata, Japan
| | - T Moriya
- Health care centre, Kitasato university, 1-15-1 Kitasato, Minami-ku, Sagamihara-shi, Kanagawa, Japan
| | - S Ishibashi
- Division of endocrinology and metabolism, school of medicine, Jichi medical university, 3311-1 Yakushiji, Shimotsuke, Tochigi, Japan
| | - S Katayama
- Kawagoe clinic, Saitama medical university, 21-7 Wakitahonchou, Kawagoe, Saitama, Japan
| | - Y Ohashi
- Department of integrated science and engineering for sustainable society, Chuo university, 1-13-27, Kasuga, Bunkyo-ku, Tokyo, Japan
| | - Y Akanuma
- The institute for adult diseases Asahi life foundation, 1-6-1 Marunouchi Chiyoda-ku, Tokyo, Japan
| | - H Sone
- Department of haematology, endocrinology and metabolism, faculty of medicine, Niigata university, 1-757 Asahi-machi, Chuo-ku, Niigata, Japan
| | - H Yamashita
- Department of ophthalmology and visual sciences, school of medicine, Yamagata university, 2-2-2 Iida-Nishi, Yamagata, Japan
| | | |
Collapse
|
46
|
Yamashita H, Matsuhara H, Miotani S, Sako Y, Matsui T, Tanaka H, Inagaki N. Artificial sweeteners and mixture of food additives cause to break oral tolerance and induce food allergy in murine oral tolerance model for food allergy. Clin Exp Allergy 2017; 47:1204-1213. [DOI: 10.1111/cea.12928] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Revised: 03/13/2017] [Accepted: 03/16/2017] [Indexed: 12/15/2022]
Affiliation(s)
- H. Yamashita
- Laboratory of Pharmacology; Department of Bioactive Molecules; Gifu Pharmaceutical University; Gifu Japan
| | - H. Matsuhara
- Laboratory of Pharmacology; Department of Bioactive Molecules; Gifu Pharmaceutical University; Gifu Japan
| | - S. Miotani
- Laboratory of Pharmacology; Department of Bioactive Molecules; Gifu Pharmaceutical University; Gifu Japan
| | - Y. Sako
- Laboratory of Pharmacology; Department of Bioactive Molecules; Gifu Pharmaceutical University; Gifu Japan
| | - T. Matsui
- Laboratory of Pharmacology; Department of Bioactive Molecules; Gifu Pharmaceutical University; Gifu Japan
- Department of Pediatrics; Graduate School of Medicine; Nagoya University; Nagoya Japan
| | - H. Tanaka
- Laboratory of Pharmacology; Department of Bioactive Molecules; Gifu Pharmaceutical University; Gifu Japan
| | - N. Inagaki
- Laboratory of Pharmacology; Department of Bioactive Molecules; Gifu Pharmaceutical University; Gifu Japan
| |
Collapse
|
47
|
Okuma K, Yamashita H, Kobayashi R, Nakagawa K. PO-0715: A phase II study of chemoradiation with triweekly cycles of nedaplatin for uterine cervical cancer. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31152-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Takahashi W, Yamashita H, Sakuramachi M, Imae T, Okuma K, Nawa K, Nakagawa K. EP-1052: Hypofractionated vs. conventional radiotherapy for early glottic cancer: a propensity score analysis. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31488-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Jingu K, Niibe Y, Yamashita H, Katsui K, Matsumoto T, Nishina T, Terahara A. PO-0682: Re-irradiation for oligo-recurrence from esophageal cancer with radiotherapy history. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31119-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Nakagawa K, Yamashita H, Saeki D, Yoshioka T, Shintani T, Kamio E, Kreissl HT, Tsang SCE, Sugiyama S, Matsuyama H. Niobate nanosheet membranes with enhanced stability for nanofiltration. Chem Commun (Camb) 2017; 53:7929-7932. [DOI: 10.1039/c7cc03911e] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Niobate nanosheets are assembled into thin membranes by a vacuum filtration.
Collapse
Affiliation(s)
- K. Nakagawa
- Center for Membrane and Film Technology
- Graduate School of Science, Technology and Innovation
- Kobe University
- Kobe 657-8501
- Japan
| | - H. Yamashita
- Department of Science and Technology
- Faculty of Science and Technology
- Tokushima University
- Tokushima 770-8506
- Japan
| | - D. Saeki
- Center for Membrane and Film Technology
- Department of Chemical Science and Engineering
- Kobe University
- Kobe 657-8501
- Japan
| | - T. Yoshioka
- Center for Membrane and Film Technology
- Graduate School of Science, Technology and Innovation
- Kobe University
- Kobe 657-8501
- Japan
| | - T. Shintani
- Center for Membrane and Film Technology
- Graduate School of Science, Technology and Innovation
- Kobe University
- Kobe 657-8501
- Japan
| | - E. Kamio
- Center for Membrane and Film Technology
- Department of Chemical Science and Engineering
- Kobe University
- Kobe 657-8501
- Japan
| | | | | | - S. Sugiyama
- Department of Science and Technology
- Faculty of Science and Technology
- Tokushima University
- Tokushima 770-8506
- Japan
| | - H. Matsuyama
- Center for Membrane and Film Technology
- Department of Chemical Science and Engineering
- Kobe University
- Kobe 657-8501
- Japan
| |
Collapse
|